Prescribing Nurtec ODT is as easy as *1, 2, 3*

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

1 Select ASPN Pharmacies, LLC in your EMR with the following address:

ASPN Pharmacies, LLC
290 West Mount Pleasant Ave
Livingston, NJ 07039
NPI: 1538590690

2 Select appropriate ICD-10-CM code for your patients.

The codes listed below may be appropriate to include with your request for your patient with migraine. Please refer to an ICD-10-CM resource for additional codes that may be applicable to your patient.

ICD-10-CM Code and Description			
G43, Migraine	G43.0, Migraine without aura	G43.1, Migraine with aura	G43.9, Migraine, unspecified

3 Select quantity and number of refills.

Nurtec ODT, 75 mg
1 Blister pack, 8 tablets
NDC: 72618-3000-02
SIG: Take one tablet by mouth daily as directed by healthcare professional for migraine. No more than one dose in 24 hrs.

or

Nurtec ODT, 75 mg
2 Blister packs, 16 tablets
NDC: 72618-3000-02
SIG: Take one tablet by mouth every other day. No more than one dose in 24 hrs.

INDICATION

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Please see additional Important Safety Information on next page.
Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont)

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

Please see full Prescribing Information.

US-RIMODT-2100766 08/2021

biohaven™ pharmaceuticals